ライフサイエンスコーパス: releasing hormone

1 achineries to liberate this key hypothalamic releasing hormone.

2 ropin-releasing hormone (CRH) or thyrotropin-releasing hormone.

3 eus was identified as containing thyrotropin-releasing hormone.

4 s to leptin and a suppression of thyrotropin-releasing hormone.

5 normalities in HIV, including growth hormone-releasing hormone.

6 ulating hormone and hypothalamic thyrotropin-releasing hormone.

7 n episodic, excitatory drive to gonadotropin-releasing hormone 1 (GnRH) neurons, the synaptic mechani

8 transcriptionally regulated by gonadotropin-releasing hormone 1 (GNRH).

9 CRH (corticotropin-releasing hormone), a peptide released from hippocampal

10 udes suppression of hypothalamic thyrotropin-releasing hormone, accounting for persistently reduced s

11 sex hormone fluctuation using a gonadotropin-releasing hormone agonist (GnRHa) and evaluated if emerg

12 ly that after 1-year follow up, gonadotropin-releasing hormone agonist (GnRHa) did not prevent chemot

13 astration and those who receive gonadotropin-releasing hormone agonist (GnRHa) therapy.

14 Luteinizing hormone-releasing hormone agonist (LHRHa; leuprolide acetate) do

15 d androgen blockade with luteinizing hormone-releasing hormone agonist and bicalutamide.

16 rian suppression induced by the gonadotropin-releasing hormone agonist leuprolide acetate, leuprolide

17 reased after treatment with the gonadotropin-releasing hormone agonist leuprolide, which inhibits the

18 rchiectomy or receipt of luteinising hormone-releasing hormone agonist or antagonist therapy started

19 Gonadotropin-releasing hormone agonist therapy is associated with hig

20 rogression and continued luteinising hormone-releasing hormone agonist therapy.

21 2 healthy, young males received gonadotropin-releasing hormone agonist treatment 1 month prior to 3 o

22 o cixutumumab added to a luteinizing hormone-releasing hormone agonist with bicalutamide versus AD al

23 every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT)

24 ndomly assigned 2:1 to a luteinizing hormone-releasing hormone agonist, bicalutamide and bevacizumab

25 rian suppression induced by the gonadotropin-releasing hormone agonist, leuprolide acetate; leuprolid

26 premenopausal women receiving a gonadotropin-releasing hormone agonist, with estrogen receptor- and/o

27 authors examined the effects of gonadotropin-releasing hormone agonist-induced ovarian suppression on

28 as achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or

29 Gonadotropin-releasing hormone agonists (GnRHa) have been suggested a

30 4.04 [95% CI, 1.88-8.69]), and gonadotropin-releasing hormone agonists (OR, 1.93 [95% CI, 1.20-3.10]

31 rivation therapy in the form of gonadotropin-releasing hormone agonists and newer antagonists, examin

32 Gonadotropin-releasing hormone agonists given with chemotherapy was a

33 androgen blockade consisting of gonadotropin-releasing hormone agonists with oral antiandrogens (OR,

34 such as surgical oophorectomy, gonadotropin-releasing hormone agonists, chemotherapy-induced ovarian

35 of 6 mutually exclusive groups: gonadotropin-releasing hormone agonists, oral antiandrogens, combined

36 Luteinising-hormone-releasing-hormone agonists (LHRHa) to treat prostate can

37 Luteinizing hormone releasing hormone analog (LHRHa, des Gly10, [D-Ala6] eth

38 Tesamorelin, a growth hormone-releasing hormone analog, specifically targets visceral

39 ter or higher received a luteinizing hormone-releasing hormone analogue and an antiandrogen agent for

40 Gonadotropin-releasing hormone analogue triptorelin, bilateral oophor

41 Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose t

42 intrauterine system (LNG-IUD), gonadotropin-releasing hormone analogues (GnRHa; nafarelin, leuprolid

43 er the administration of luteinizing hormone-releasing hormone analogues (LHRHa) during chemotherapy

44 Gonadotropin-releasing hormone analogues and laparoscopic ablation or

45 (castration via orchiectomy or gonadotropin-releasing hormone analogues) suppresses circulating test

46 Gonadotropin-releasing hormone analogues, danazol, and depot progesta

47 corticotropin-releasing factor, thyrotropin-releasing hormone and calcitonin gene-related peptide) i

48 ticotrophin-releasing hormone or thyrotropin-releasing hormone and do not express arginine vasopressi

49 ediated by reduced secretion of gonadotropin-releasing hormone and our results support the involvemen

50 ed hypothalamic expression of corticotrophin-releasing hormone and oxytocin, neuropeptides known to c

51 mber of DMV neurones excited by thyrotrophin-releasing hormone and the gastric motility response to D

52 the endogenous natural ligand, gonadotropin releasing hormone, and an agonist that is specific for t

53 tocin, vasopressin, enkephalin, thyrothropin-releasing hormone, and corticotropin-releasing factor im

54 .e., C-reactive protein (CRP), corticotropin-releasing hormone, and cytokines) were compared among te

55 prohormone processing of proinsulin, pro-GH-releasing hormone, and proghrelin in association with re

56 mitters such as glutamate, GABA, thyrotropin releasing hormone, and substance P encoded by the Tachyk

57 tide markers (cholecystokinin, corticotropin-releasing hormone, and tachykinin 1) label sleep-promoti

58 Gonadotropin releasing hormone antagonism successfully reduced circul

59 ive hormone production using a gonadotrophin-releasing hormone antagonist (GnRHant) for 10 days, with

60 g hormone and administration of gonadotropin-releasing hormone antagonist to prevent premature ovulat

61 stage in both immature mice and gonadotropin releasing hormone antagonist-treated adult mice.

62 n T through administration of a gonadotropin releasing hormone antagonist.

63 luster express a reporter for corticotrophin-releasing hormone (Bar(CRH) ).

64 rs28365143 variant within the corticotropin-releasing hormone binding protein (CRHBP) gene predicted

65 We demonstrate that corticotropin-releasing-hormone-binding protein (CRHBP), an antagonist

66 creased somewhat by exposure to gonadotropin-releasing hormone but are not necessarily linked to Cga

67 Using a corticotropin releasing hormone-cre driver X tdTomato reporter mouse,

68 hat encode the stress hormones corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone.

69 ysiological concentrations of corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) c

70 o hypothalamic secretagogues, corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) t

71 o hypothalamic secretagogues, corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) t

72 The corticotropin-releasing hormone (CRH) and its type 1 receptor (CRHR1)

73 and stress molecules including corticotropin-releasing hormone (CRH) and neurotensin (NT), secreted i

74 ormone (ACTH) by hypothalamic corticotrophin-releasing hormone (CRH) and then stimulation of the adre

75 show that a constant level of corticotrophin-releasing hormone (CRH) can activate a dynamic pituitary

76 sh with transgenically labeled corticotropin-releasing hormone (CRH) cells, which represent a major r

77 l-genetic approaches to reduce corticotropin-releasing hormone (Crh) expression in the central nucleu

78 the production and release of corticotropin-releasing hormone (CRH) from the paraventricular nucleus

79 he suppression of hypothalamic corticotropin-releasing hormone (CRH) gene expression and potently enh

80 ion between macroautophagy and Corticotropin Releasing Hormone (Crh) in the gut.

81 cluster of neurons expressing corticotropin-releasing hormone (Crh) in the pontine micturition cente

82 Corticotropin-releasing hormone (CRH) is a central integrator in the b

83 Corticotropin-releasing hormone (CRH) is a major regulator of the hypo

84 Corticotropin releasing hormone (CRH) is disrupted in individuals with

85 Corticotropin-releasing hormone (CRH) is secreted under stress and reg

86 atory and inhibitory inputs to corticotropin-releasing hormone (CRH) neurons in the hypothalamic para

87 xiety-related behaviours, and corticotrophin releasing hormone (crh) neurons, key regulators of the s

88 ansmit signals to hypothalamic corticotropin-releasing hormone (CRH) neurons, which control stress ho

89 atory synaptic strength in PVN corticotropin-releasing hormone (CRH) neurons, with GLP-1R activation

90 actions of corticosterone and corticotropin-releasing hormone (CRH) on synaptic physiology and dendr

91 xytocin, arginine vasopressin, corticotropin-releasing hormone (CRH) or thyrotropin-releasing hormone

92 corticosterone and hippocampal corticotropin-releasing hormone (CRH) permeate memory-forming hippocam

93 u receptor 2 and signaling via corticotropin releasing hormone (Crh) receptor 1.

94 adigm posits that hypothalamic corticotropin-releasing hormone (CRH) regulates neuroendocrine functio

95 Corticotropin-releasing hormone (CRH) released from the paraventricula

96 The corticotropin-releasing hormone (CRH) system coordinates neuroendocrin

97 The corticotrophin-releasing hormone (CRH) system integrates the stress res

98 n, increased activation of the corticotropin-releasing hormone (CRH) system within the extended amygd

99 (WM) deficits; changes to the corticotropin-releasing hormone (CRH) system; and structural, function

100 Glucocorticoids and corticotropin releasing hormone (CRH) underlie the physiology of chang

101 nd release of the neuropeptide corticotropin-releasing hormone (CRH) within the hippocampus during st

102 ive preclinical data implicate corticotropin-releasing hormone (CRH), acting through its CRH1 recepto

103 Although corticotropin-releasing hormone (CRH), produced by parvocellular neuro

104 ected and processed to measure corticotropin-releasing hormone (CRH), urocortin (Ucn), beta-endorphin

105 stimulating the expression of corticotropin-releasing hormone (CRH), urocortin, proopiomelanocortin

106 for vasotocin, mesotocin (MT), corticotropin-releasing hormone (CRH), vasoactive intestinal polypepti

107 4), a homolog of the mammalian corticotropin-releasing hormone (CRH), were specifically activated by

108 e stress-released neuropeptide corticotropin-releasing hormone (CRH), which influence the integrity o

109 regulator of the HPA axis is corticotrophin-releasing hormone (CRH), which is made in the parventric

110 have described the effects of corticotropin-releasing hormone (CRH), which is released from inflamed

111 , we have virally traced local corticotropin-releasing hormone (CRH)-expressing inhibitory interneuro

112 e genomes for genes resembling corticotropin-releasing hormone (CRH).

113 XT neurons that co-express the corticotropin-releasing hormone (CRH).

114 the cortisol-regulating genes, corticotropin releasing hormone (CRH; P=0.05) and glucocorticoid recep

115 Furthermore, endogenous corticotropin-releasing hormone(+) (CRH(+)) LC inputs from the amygdal

116 n addition, we discovered that corticotropin-releasing hormone-expressing cells contain GABAergic and

117 tion resulted from diminished growth hormone-releasing hormone expression in the hypothalamus and, su

118 tance, resulting in increased corticotrophin-releasing hormone expression, chronic hypercortisolism,

119 The corticotropin-releasing hormone family mediates functional responses i

120 chum salmon (Oncorhynchus keta), thyrotropin-releasing hormone gene expression increased immediately

121 Pretreatment with the growth hormone-releasing hormone (GHRH) agonist, JI-36, significantly e

122 Because growth hormone-releasing hormone (GHRH) and GHRH receptor (GHRH-R) are

123 th inadequate compensation by Growth hormone-releasing hormone (GHRH) and Growth hormone (GH), undera

124 fects of agonistic analogs of growth hormone-releasing hormone (GHRH) and their mechanism of action w

125 clinical studies suggest that growth hormone-releasing hormone (GHRH) antagonists effectively shrink

126 in, called SXN101742, contains a modified GH-releasing hormone (GHRH) domain and the endopeptidase do

127 growth-stimulatory peptides, growth hormone-releasing hormone (GHRH) for GHRH-neurons and somatostat

128 Growth hormone-releasing hormone (GHRH) has been previously shown to ha

129 Agonists of growth hormone-releasing hormone (GHRH) have been previously reported t

130 act of targeted disruption of growth hormone-releasing hormone (GHRH) in mice on longevity and the pu

131 Antagonists of hypothalamic growth hormone-releasing hormone (GHRH) inhibit growth of various malig

132 Growth hormone-releasing hormone (GHRH) is a hypothalamic neuropeptide

133 Hypothalamic growth hormone-releasing hormone (GHRH) neurons orchestrate body growth

134 MC), neuropeptide Y (NPY) and growth hormone releasing hormone (GHRH) neurons, regulates feeding, ene

135 It has been shown that growth hormone-releasing hormone (GHRH) reduces cardiomyocyte (CM) apop

136 The hypothalamic growth hormone-releasing hormone (GHRH) regulates the release of GH by

137 ed serum GH levels, a greater response to GH releasing hormone (GHRH) stimulation along with lower we

138 ion using a potent agonist of growth-hormone-releasing hormone (GHRH) to promote islet viability and

139 CSCs) express the receptor of growth hormone releasing hormone (GHRH), activation of which improves i

140 the hypothalamic polypeptide growth hormone-releasing hormone (GHRH), as well as for GHRH itself, in

141 in-releasing factor (CRF) and growth hormone-releasing hormone (GHRH), suggesting novel interactions

142 of the multiple activities of growth hormone-releasing hormone (GHRH), we hypothesized that pretreatm

143 nthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH or LHRH), is the active pharmace

144 Gonadotropin-releasing hormone (GnRH) acts at gonadotropes to direct

145 Gonadotropin-releasing hormone (GnRH) agonists (e.g., triptorelin) ar

146 ART treatment cycles receiving gonadotropin-releasing hormone (GnRH) agonists and recombinant follic

147 Studies of the use of gonadotropin-releasing hormone (GnRH) agonists to protect ovarian fun

148 iandrogens (AA), 26,959 were on gonadotropin-releasing hormone (GnRH) agonists, and 3,747 underwent s

149 ized trial evaluated the use of gonadotropin-releasing hormone (GnRH) analog triptorelin to preserve

150 Women treated with gonadotropin-releasing hormone (GnRH) analogs may develop enteric neu

151 inasteride, spironolactone, and gonadotropin-releasing hormone (GnRH) analogs.

152 Both gonadotropin-releasing hormone (GnRH) and activins, members of the tr

153 te meiosis, TGF-beta signaling, gonadotropin-releasing hormone (GnRH) and epidermal growth factor rec

154 In vertebrates, gonadotropin-releasing hormone (GnRH) and gonadotropin-inhibitory hor

155 the synthesis and/or release of gonadotropin-releasing hormone (GnRH) and gonadotropins.

156 diol (E2) regulating release of gonadotropin releasing hormone (GnRH) and luteinizing hormone (LH) ar

157 Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to

158 Congenital gonadotropin-releasing hormone (GnRH) deficiency manifests as absent

159 Release of gonadotropin releasing hormone (GnRH) from the medial basal hypothala

160 with an inherited deficiency in gonadotropin-releasing hormone (GnRH) have impaired sexual reproducti

161 pressed basal transcription and gonadotropin-releasing hormone (GnRH) induction of both the murine an

162 minence (ME) where they release gonadotropin-releasing hormone (GnRH) into a specialized capillary ne

163 Gonadotropin-releasing hormone (GnRH) is a key regulator of reproduct

164 Gonadotropin-releasing hormone (GnRH) is a trophic peptide hormone sy

165 Gonadotropin-releasing hormone (GnRH) is a trophic peptide hormone th

166 Gonadotropin-releasing hormone (GnRH) is secreted in brief pulses fro

167 Gonadotropin-releasing hormone (GnRH) is secreted in brief pulses tha

168 Gonadotropin-releasing hormone (GnRH) is the central regulator of gon

169 The gonadotropin-releasing hormone (GnRH) is the master regulator of fert

170 The gonadotropin-releasing hormone (GnRH) is the master regulator of fert

171 We have previously shown that gonadotropin-releasing hormone (GnRH) ligand-independently activates

172 The gonadotropin-releasing hormone (GnRH) neuron is the pivotal control c

173 rons have been shown to inhibit gonadotropin-releasing hormone (GnRH) neuronal activity and hence rep

174 lases (HDACs) in the control of gonadotropin releasing hormone (GnRH) neuronal development is unknown

175 nfluence on the activity of the gonadotropin-releasing hormone (GnRH) neuronal network controlling fe

176 entral driver of fertility: the gonadotropin releasing hormone (GnRH) neuronal system.

177 Estradiol feedback regulates gonadotropin-releasing hormone (GnRH) neurons and subsequent luteiniz

178 Gonadotropin-releasing hormone (GnRH) neurons are born in the nasal p

179 Gonadotropin-releasing hormone (GnRH) neurons are neuroendocrine cell

180 Gonadotropin-releasing hormone (GnRH) neurons are the final common pa

181 Gonadotropin-releasing hormone (GnRH) neurons are the final output ne

182 The gonadotropin-releasing hormone (GnRH) neurons are the key cells regul

183 ons act cooperatively to excite gonadotropin-releasing hormone (GnRH) neurons during positive feedbac

184 tioning in mammals depends upon gonadotropin-releasing hormone (GnRH) neurons generating a pulsatile

185 controlling the activity of the gonadotropin-releasing hormone (GnRH) neurons in vivo to establish th

186 Hypothalamic gonadotropin-releasing hormone (GnRH) neurons integrate the multiple

187 ypogonadism to study effects of gonadotropin releasing hormone (GnRH) neurons on neuronal circuits co

188 Gonadotropin-releasing hormone (GnRH) neurons originate outside the C

189 Gonadotropin-releasing hormone (GnRH) neurons produce the central out

190 and electrophysiology, that the gonadotropin-releasing hormone (GnRH) neurons that control mammalian

191 radiol on proestrus to activate gonadotropin-releasing hormone (GnRH) neurons that, in turn, trigger

192 which estradiol (E2) regulates gonadotropin-releasing hormone (GnRH) neurons to control fertility ar

193 erminal Ca(2+) is controlled in gonadotropin-releasing hormone (GnRH) neurons via action potentials a

194 tes reproduction by stimulating gonadotropin-releasing hormone (GnRH) neurons via the kisspeptin rece

195 mal steroid hormone feedback to gonadotropin-releasing hormone (GnRH) neurons.

196 in cilia projecting from mouse gonadotropin-releasing hormone (GnRH) neurons.

197 nd depends upon the activity of gonadotropin-releasing hormone (GnRH) neurons.

198 drive the pulsatile activity of gonadotropin-releasing hormone (GnRH) neurons.

199 ain regulates fertility through gonadotropin-releasing hormone (GnRH) neurons.

200 n by acting on gonadotropes and gonadotropin-releasing hormone (GnRH) neurons.

201 Hypothalamic gonadotropin-releasing hormone (GnRH) plays a critical role in reprod

202 The gonadotropin-releasing hormone (GnRH) receptor is a drug target for c

203 ure of information transfer via gonadotropin-releasing hormone (GnRH) receptors (GnRHR) to extracellu

204 Pulsatile gonadotropin-releasing hormone (GnRH) release is critical for the cen

205 modulating the tonic pulsatile gonadotropin-releasing hormone (GnRH) release.

206 ion by brain-secreted pulses of gonadotropin-releasing hormone (GnRH) represents a longstanding puzzl

207 uisition of a mature pattern of gonadotropin-releasing hormone (GnRH) secretion from the CNS is a hal

208 Gonadotropin-releasing hormone (GnRH) secretion is regulated by estra

209 components in the regulation of gonadotropin-releasing hormone (GnRH) secretion.

210 sm had a measurable response to gonadotropin-releasing hormone (GnRH) stimulation, suggesting that it

211 e is an inherited deficiency of gonadotropin-releasing hormone (GnRH) that is characterized by hypogo

212 IKK-beta and NF-kappaB inhibit gonadotropin-releasing hormone (GnRH) to mediate ageing-related hypot

213 ropin hormones are regulated by gonadotropin-releasing hormone (GnRH) via MAPK signaling pathways tha

214 neurons that express genes for gonadotropin-releasing hormone (GnRH), a G-protein-coupled receptor f

215 express an antibody that binds gonadotropin-releasing hormone (GnRH), a master regulator of reproduc

216 tropin-releasing hormone (TRH), gonadotropin-releasing hormone (GnRH), and kisspeptin.

217 hypothalamic neurons secreting gonadotropin-releasing hormone (GnRH), the neuropeptide controlling r

218 Gonadotropin-releasing hormone (GnRH)-expressing neurons migrate alon

219 ry-gonadal axis is dependent on gonadotropin-releasing hormone (GNRH)-stimulated synthesis and secret

220 rease in pulsatile secretion of gonadotropin-releasing hormone (GnRH).

221 with regulation by activins and gonadotropin releasing hormone (GnRH).

222 rk that drives the secretion of gonadotropin-releasing hormone (GnRH).

223 duction in mammals by secreting gonadotropin-releasing hormone (GnRH).

224 secreting the 'master molecule' gonadotropin-releasing hormone (GnRH).

225 n requires pulsatile release of gonadotropin-releasing hormone (GnRH1) from the hypothalamus.

226 he receptor of the neuropeptide gonadotropin-releasing hormone (GnRHR) is unique among the G protein-

227 type D with a fragment of the growth hormone releasing hormone, has previously revealed promising res

228 ex restrains the amygdala, the corticotropin-releasing hormone/hypothalamic-pituitary-adrenal (CRH/HP

229 de homologous to the vertebrate gonadotropin-releasing hormone, is downregulated as workers become ga

230 ated PTD showed higher CRP and corticotropin-releasing hormone levels.

231 (ACTH) and hypothalamic luteinizing hormone-releasing hormone (LHRH) agonist, [D-Trp6]LHRH.

232 ents on BPH therapy with luteinizing hormone-releasing hormone (LHRH) antagonist are also reviewed an

233 fied synthetic analog of luteinizing hormone-releasing hormone (LHRH) as a targeting moiety specific

234 able fragment (scFv) and luteinizing hormone releasing hormone (LHRH) peptide, resulting in specific

235 ortantly, SSA induced by luteinizing hormone-releasing hormone (LHRH) receptor antagonism bypassed th

236 Irradiation of luteinizing hormone releasing hormone (LHRH), growth hormone releasing hexap

237 ceived letrozole (plus a luteinizing hormone-releasing hormone [LHRH] agonist if premenopausal).

238 nating serotonergic control of corticotropin-releasing hormone-mediated excitation of the BNST.

239 in or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and or

240 aventricular hypothalamic CRH (corticotropin-releasing hormone) neuroendocrine neurons shortly after

241 in responses, suggesting normal gonadotropin-releasing hormone neuronal and gonadotrope function.

242 and send axonal projections to gonadotropin-releasing hormone neurons and regulate reproductive func

243 In immortalized immature gonadotropin-releasing hormone neurons endogenously expressing TRPC1,

244 eus tractus solitarii (NTS) to corticotropin releasing hormone neurons in the paraventricular nucleus

245 PC1 suppressed the migration of gonadotropin-releasing hormone neurons without affecting cell prolife

246 including direct innervation of gonadotropin releasing hormone neurons.

247 aging in the nerve terminals of gonadotropin-releasing hormone neurons.

248 membrane receptors but not by corticotropin-releasing hormone or dexamethasone.

249 these neurons largely express corticotrophin-releasing hormone or thyrotropin-releasing hormone and d

250 duction relies on hypothalamic gonadotrophin-releasing hormone output, and most cells producing repro

251 iology, specifically placental corticotropin-releasing hormone (pCRH).

252 f RTN activity by Substance P or thyrotropin-releasing hormone, previously identified neuromodulators

253 The type 1 corticotropin-releasing hormone receptor (CRH-R1) influences biologica

254 ficial effects of agonists of growth hormone-releasing hormone receptor (GHRH-R) in heart failure mod

255 r (L-NAME) and stimulation of growth hormone-releasing hormone receptor (GHRHR) with GHRH agonists au

256 tumor cells overexpressing the gonadotropin-releasing hormone receptor (GnRH-R).

257 Pharmacoperones of the gonadotropin releasing hormone receptor (GnRHR) have efficacy in cell

258 rtitioning mutant conformers of gonadotropin-releasing hormone receptor (GnRHR), a G protein-coupled

259 stimulates transcription of the thyrotropin-releasing hormone receptor (TRHR) by negative modulation

260 -binding site defined--for the corticotropin-releasing hormone receptor 1 (CRF1R)--which was located

261 Corticotropin-releasing hormone receptor 1 (CRHR1) activates G protein

262 Variations in the corticotropin-releasing hormone receptor 1 (CRHR1) gene have been foun

263 In addition, GR and corticotropin-releasing hormone receptor 1 (CRHR1) genotypes contribut

264 and alleviated by antalarmin (corticotropin releasing hormone receptor 1 antagonist).

265 ein 2)), chromosome 17 (CRHR1 (corticotropin-releasing hormone receptor 1) and MAPT (microtubule-asso

266 Activation of corticotropin-releasing hormone receptor 2 (CRHR2) in the colonic muco

267 Thyrotropin-releasing hormone receptor type 2 (TRH-R2), not TRH-R1,

268 ve ganglion cells (dsGCs): TRHR (thyrotropin-releasing hormone receptor) and Drd4 (dopamine receptor

269 mbrane progestin receptor, the corticotropin releasing hormone receptor, and the 5HT1a serotonin rece

270 hours significantly increases corticotropin-releasing hormone receptor-1 (CRHR-1) mRNA and protein e

271 icant three-way interaction on corticotropin-releasing hormone receptor-1 (Crhr1) gene expression, in

272 gold nanorods (gGNRs) promotes gonadotropin releasing hormone receptor-mediated internalization and

273 e cells, and co-localized with corticotropin-releasing hormone receptors in the latter.

274 responses by binding to type 2 corticotropin-releasing hormone receptors.

275 , highlighting a role of SET in gonadotropin-releasing hormone regulation of gene expression.

276 s1 promoter disrupted pulsatile gonadotropin-releasing hormone release, delayed puberty and compromis

277 Gene expression of salmon gonadotropin-releasing hormone (sGnRH) and NR1 increased in the adult

278 g sensitization of the NKB-NK3R-gonadotropin-releasing hormone signaling pathway under metabolic dist

279 itial and replication samples: corticotropin-releasing hormone signaling, cardiac beta-adrenergic sig

280 nalyses revealed enrichment of corticotropin-releasing hormone signaling, GNRH signaling, and/or CDK5

281 flammation, adipocytokines, and thyrotrophin-releasing hormone signaling.

282 and is released in response to gonadotropin-releasing hormone, similar to LH.

283 eptors, and by the hypothalamic gonadotropin-releasing hormone through activation of PKA.

284 availability via leptin-induced thyrotropin-releasing hormone/thyroid-stimulating hormone expression

285 er factors control secretion of gonadotropin-releasing hormone to determine initiation of puberty.

286 satile, coordinated delivery of gonadotropin-releasing hormone to the pituitary and the resulting sur

287 om subsets of neurons expressing thyrotropin-releasing hormone (TRH) and pituitary adenylate cyclase-

288 yroid (HPT) axis hormones, i.e., thyrotropin-releasing hormone (TRH) and thyrotropin (TSH), are expre

289 loop that inhibits production of thyrotropin-releasing hormone (TRH) in the mediobasal hypothalamus (

290 Thyrotropin-releasing hormone (TRH) increases activity and decreases

291 In vertebrates thyrotropin-releasing hormone (TRH) is a highly conserved neuropepti

292 The neuropeptide thyrotropin-releasing hormone (TRH) is recognized to play an importa

293 phe-derived serotonin (5-HT) and thyrotropin-releasing hormone (TRH) play important roles in fundamen

294 Here we show that mouse thyrotropin-releasing hormone (TRH) receptors, subtypes 2 and 1(TRH-

295 sion of Sim1, oxytocin (OXT) and thyrotropin releasing hormone (TRH) was reduced by about 50%.

296 ma-aminobutyric acid (GABA), and thyrotropin-releasing hormone (TRH) were colocalized with histamine

297 nin-concentrating hormone (MCH), thyrotropin-releasing hormone (TRH), gonadotropin-releasing hormone

298 activated thyroid-stimulating hormone (TSH)-releasing hormone (TRH)-positive neurons in the paravent

299 , and do not express oxytocin, corticotropin-releasing hormone, vasopressin, or prodynorphin.

300 on requires timely secretion of gonadotropin-releasing hormone, which is controlled by a complex exci